SCHEMBL2835202

SCHEMBL2835202

NNC(=O)c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.65
MAPT P10636 1/20 0.65
PARP10 Q53GL7 1/20 0.63
HPGD P15428 3/20 0.62
CA1 P00915 2/20 0.61
CA2 P00918 2/20 0.61
MMP1 P03956 1/20 0.61
PGR P06401 1/20 0.61
ERCC5 P28715 1/20 0.59
FEN1 P39748 1/20 0.59
CA12 O43570 1/20 0.58
MMP2 P08253 1/20 0.58
CA9 Q16790 1/20 0.58
MAPK14 Q16539 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
LMNA P02545 2/20 0.56
HTT P42858 2/20 0.56
CYP3A4 P08684 1/20 0.56
MMP13 P45452 1/20 0.56
HDAC3 O15379 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4176758 0.92 CA1 (0.70) ALDH1A1MAPTPARP10HPGDCA1
SCHEMBL11132687 0.85 PARP10 (0.63) ALDH1A1MAPTPARP10HPGDCA1
SCHEMBL6539464 0.84 MAPT (0.69) ALDH1A1MAPTPARP10HPGDCA1
SCHEMBL31295303 0.84 HDAC8 (0.73) ALDH1A1PARP10ERCC5FEN1SMN1; SMN2
SCHEMBL2830822 0.84 HDAC8 (0.73) ALDH1A1PARP10ERCC5FEN1SMN1; SMN2
SCHEMBL16827365 0.83 CA1 (0.59) ALDH1A1MAPTPARP10HPGDCA1
SCHEMBL13188232 0.82 HDAC8 (0.71) PARP10HPGDCA1CA2MMP1
SCHEMBL3533538 0.82 RAB9A (0.62) ALDH1A1HPGDCA1CA2MAPK14
SCHEMBL24209329 0.81 ERCC5 (0.70) ALDH1A1MAPTPARP10HPGDMMP1
SCHEMBL28761123 0.81 PARP10 (0.59) PARP10HPGDCA1CA2MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479856-B2 Pharmaceutical compounds for the treatment of complement mediated disorders ACHILLION PHARMACEUTICALS, INC. (US) 2025-11-25 US disclosed
US-20230085372-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2023-03-16 US disclosed
CN-113416266-A Aromatic hydrazide compound-cyclodextrin inclusion compound and preparation method thereof 湖北工业大学 2021-09-21 CN disclosed
US-10906890-B2 Triazole phenyl compounds as agonists of the APJ receptor AMGEN INC. (US) 2021-02-02 US disclosed
EP-3541810-B1 TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AMGEN INC (US) 2020-12-23 EP disclosed
US-10870618-B2 Histone deacetylase inhibitors and uses thereof MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2020-12-22 US disclosed
US-20190308932-A1 HISTONE DEACETYLASE INHIBITORS AND USES THEREOF MEDICAL UNIVERSITY OF SOUTH CAROLINA 2019-10-10 US disclosed
US-20190284173-A1 TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AMGEN INC. (US) 2019-09-19 US disclosed
WO-2018071740-A1 HISTONE DEACETYLASE INHIBITORS AND USES THEREOF MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2018-04-19 WO disclosed
US-20100168101-A1 OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2010-07-01 US disclosed
US-7696231-B2 Oxindole hydrazide modulators of protein tyrosine phosphatases (PTPs) LABORATOIRES SERONO SA (CH) 2010-04-13 US disclosed
US-20050065118-A1 Organosulfur inhibitors of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2005-03-24 US disclosed
US-20050043388-A1 Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps) APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. 2005-02-24 US disclosed
EP-1446110-A2 ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES Structural Bioinformatics Inc. (US) 2004-08-18 EP disclosed
EP-1439834-A1 OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) Applied Research Systems ARS Holding N.V. (AN) 2004-07-28 EP disclosed
WO-2003037328-A1 OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2003-05-08 WO disclosed
WO-2003032916-A2 ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES STRUCTURAL BIOINFORMATICS INC. (US) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10870618-B2 Histone deacetylase inhibitors and uses thereof HDAC1, HDAC5, HDAC3 ALDH1A1 222/4885MAPT 3198/4885PARP10 237/4885
US-20190284173-A1 TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AGTR1, AGTR2, TBXA2R ALDH1A1 2110/4885MAPT 3966/4885PARP10 1486/4885
US-12479856-B2 Pharmaceutical compounds for the treatment of complement mediated disorders C5, CFH, C1QBP ALDH1A1 2814/4885MAPT 1226/4885PARP10 533/4885
US-20050043388-A1 Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps) PTPRO, PTPRE, PTPRZ1 ALDH1A1 774/4885MAPT 4427/4885PARP10 4138/4885
US-20050065118-A1 Organosulfur inhibitors of tyrosine phosphatases PTPRS, PTPRJ, PTPRCAP ALDH1A1 961/4885MAPT 3318/4885PARP10 3907/4885
US-20190308932-A1 HISTONE DEACETYLASE INHIBITORS AND USES THEREOF HDAC1, HDAC5, HDAC3 ALDH1A1 222/4885MAPT 3198/4885PARP10 237/4885
US-10906890-B2 Triazole phenyl compounds as agonists of the APJ receptor AGTR1, AGTR2, TBXA2R ALDH1A1 2110/4885MAPT 3966/4885PARP10 1486/4885
US-20100168101-A1 OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) PTPRO, PTPRE, PTPRZ1 ALDH1A1 798/4885MAPT 4446/4885PARP10 4132/4885
US-20230085372-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C5, CFH, C1QBP ALDH1A1 2814/4885MAPT 1226/4885PARP10 533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.